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In a 24-month prospective, randomized, multicenter,
open-label study, de novo liver transplant patients
were randomized at 30 days to everolimus (EVR) þ
Reduced tacrolimus (TAC; n ¼ 245), TAC Control
(n ¼ 243) or TACElimination (n ¼ 231). Randomization
to TAC Elimination was stopped prematurely due to a
significantly higher rate of treated biopsy-proven acute
rejection (tBPAR). The incidence of the primary efficacy
endpoint, composite efficacy failure rate of tBPAR,
graft loss or death postrandomizationwas similar with
EVR þ Reduced TAC (10.3%) or TAC Control (12.5%) at
month 24 (difference 2.2%, 97.5% confidence interval
[CI] 8.8%, 4.4%). BPAR was less frequent in the
EVR þ Reduced TAC group (6.1% vs. 13.3% in TAC
Control, p ¼ 0.010). Adjusted change in estimated
glomerular filtration rate (eGFR) from randomization
to month 24 was superior with EVR þ Reduced TAC
versus TAC Control: difference 6.7 mL/min/1.73 m2
(97.5% CI 1.9, 11.4 mL/min/1.73 m2, p ¼ 0.002).
Among patients who remained on treatment, mean
(SD) eGFR at month 24 was 77.6 (26.5) mL/min/
1.73 m2 in the EVR þ Reduced TAC group and 66.1
(19.3) mL/min/1.73 m2 in the TAC Control group
(p < 0.001). Study medication was discontinued due
to adverse events in 28.6% of EVR þ Reduced TAC and
18.2% of TAC Control patients. Early introduction of
everolimus with reduced-exposure tacrolimus at
1 month after liver transplantation provided a signifi-
cant and clinically relevant benefit for renal function at
2 years posttransplant.
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Introduction
Minimizing exposure to calcineurin inhibitors (CNIs) following
solid organ transplantation is a well-established clinical
objective. Use of mammalian target of rapamycin (mTOR)
inhibitors to support CNI minimization is a highly promising
approach, but it remains unclear whether long-term mainte-
nance of low-exposure CNI therapy or CNI elimination is a
preferable strategy. Data from kidney transplantation sug-
gest that although CNI reduction can be undertaken without
loss of efficacy in the presence of the mTOR inhibitor
everolimus (1), tubulointerstitial and glomerular damage
continues in the presence of reduced CNI exposure (2).
Experience with the use of everolimus to minimize CNI
exposure following liver transplantation ismore limited and is
largely related to CNI-free regimens. One prospective (3) and
one retrospective (4) study in maintenance liver transplant
patients have suggested that the benefit of conversion to
everolimus from CNI therapy appears to be concentrated in
patients with greater residual renal function at the time of
conversion (3,4). Two randomized trials have explored early
switch from CNI to everolimus therapy in liver transplanta-
tion (5,6). Masetti et al. (5) observed significantly higher renal
function in patients maintained on everolimus monotherapy
from day 30 versus cyclosporine with mycophenolate
mofetil. In the PROTECT study, conversion from tacrolimus
or cyclosporine to everolimus (with or without steroids) over
an 8-week period starting on day 30 resulted in higher renal
function at 12 months posttransplant based on the four-
variable Modification of Diet in Renal Disease (MDRD4)
formula without loss of efficacy (6).
In a prospective trial, 719 patients were randomized at
1 month after liver transplantation to continue a standard
tacrolimus-based regimen or start everolimus with re-
duced-exposure tacrolimus or tacrolimus elimination. The
primary results at month 12 posttransplant have been
reported previously (7). Following completion of the entire
24-month study, the current manuscript focuses on the
evolution of renal function from randomization to month 24
posttransplant.
Methods
Study design
This was a 24-month prospective, randomized, multicenter, three-arm,
parallel-group, open-label study in de novo liver transplant recipients
undertaken at transplant centers in 19 countries in Europe, North America
and South America and other countries including Australia, Russia and Israel
during January 2008 to April 2012.
After a run-in period during which the immunosuppression regimen was
identical for all groups, patients were randomized at 30 (5) days
posttransplant in a 1:1:1 ratio to one of three treatment groups: (i)
EVR þ Reduced TAC; (ii) TAC Control or (iii) TAC Elimination. Patients
were stratified prior to randomization according to pretransplant hepatitis C
virus (HCV) status and quartiles of renal function (based on estimated
glomerular filtration rate [eGFR] according to the MDRD4 formula (8)).
Randomization to the TAC Elimination arm was stopped in April 2010, when
approximately 690 patients had been randomized in total. This followed a
recommendation from the independent Data Monitoring Committee based
on a significantly higher rate of acute rejections leading to study
discontinuation clustered around the time of tacrolimus withdrawal versus
the other two treatment arms. The study protocol was amended to stop
recruitment to the TAC Elimination arm, and eligible patients were
subsequently randomized equally between the EVR þ Reduced TAC and
TAC Control groups. Patients already randomized to TAC Elimination who
were 180 days postrandomization were converted to standard treatment,
whereas those who were >180 days postrandomization with stable graft
function could continue on their assigned TAC Elimination regimen.
The trial was conducted in accordance with the Declaration of Helsinki and
Good Clinical Practice guidelines and all patients provided written informed
consent.
Study endpoints
The primary efficacy endpoint was the composite efficacy failure rate of
treated biopsy-proven acute rejection (tBPAR), graft loss or death since
randomization. tBPAR was defined as treated acute rejection with rejection
activity index (RAI)3 according to Banff 1997 criteria (9). The key secondary
endpoint was the change in renal function from randomization as assessed
by eGFR using theMDRD4 formula (10). These endpointswere revised from
the original endpoints after implementation of the protocol amendment. The
original co-primary endpoints were noninferior composite efficacy failure
rate of death, graft loss or loss to follow-up, and superior renal function (as
assessed by eGFR using the MDRD4 formula).
Inclusion and exclusion criteria
Adult (18–70 years) recipients of a primary full-size liver transplant from a
deceased donor who had received tacrolimus and corticosteroids (with or
withoutmycophenolic acid) from time of transplant were eligible to enter the
run-in period. Key inclusion criteria at the time of randomization comprised (i)
eGFR (MDRD4) 30 mL/min/1.73 m2; (ii) acceptable graft function (aspar-
tate aminotransferase [AST], alanine aminotransferase [ALT] and total
bilirubin levels3 times the upper limit of normal, with alkaline phosphatase
5 times the upper limit of normal) and (iii) tacrolimus trough concentration
8 ng/mL in theweek prior to randomization. Key exclusion criteria included
hepatocellular carcinoma (HCC) that did not fulfill Milan criteria (11,12) as per
explant histology, and receipt of antibody induction therapy. To enter the run-
in period, patients were also excluded if urine protein excretion was 1.0 g/
day. At the point of randomization, key additional inclusion criteria were:
Doppler ultrasound showing the patency of hepatic artery, hepatic and portal
veins; confirmation of eGFR 30 mL/min/1.73 m2; and absence of acute
rejection requiring T cell depleting antibody therapy or1 episode of steroid-
sensitive rejection during the run-in period.
Immunosuppression
In the EVR þ Reduced TAC arm, everolimus therapy was initiated at a dose
of 1.0 mg b.i.d. within 24 h of randomization, adjusted from day 5 to target a
trough (C0) concentration in the range 3–8 ng/mL. Once everolimus trough
concentrationwaswithin this range, tacrolimus dosewas tapered to achieve
a trough concentration of 3–5 ng/mL by week 3 after randomization. In the
TAC Control arm, the target tacrolimus trough concentration was 8–12 ng/
mL until month 4 posttransplant and 6–10 ng/mL thereafter. In the TAC
Elimination arm, everolimus was administered as in the EVR þ Reduced
TAC group until month 4 posttransplant, when the target trough concentra-
tion range had to be increased to 6–10 ng/mL. Tacrolimus elimination was
then started and was to be completed by the end of month 4 posttransplant.
Corticosteroids were to be initiated in all patients at the time of transplant
and administered according to local practice (including peri-operative
intravenous corticosteroids), with a minimum oral dose of 5 mg
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prednisolone/day after randomization to be continued until at least month 6
posttransplant. Mycophenolic acid, if used, was administered as per local
practice but had to be discontinued by the time of randomization.
Statistical analysis
No inferential statistical comparisons were undertaken for the TAC
Elimination group due to premature discontinuation of recruitment and
extensive conversion of patients in this arm to standard therapy.
The primary endpoint of composite efficacy failure atmonth 12was analyzed
based on a noninferiority test with a prespecified 12% noninferiority margin
at a one-sided 0.0125 significance level. The incidence of the composite
efficacy failure endpoint was estimated using the Kaplan–Meier product-
limit formula and standard error (SE) based on Greenwood’s formula. The
incidence rates of the composite efficacy failure endpoint at month 24, as
well as its components at months 12 and 24, were also estimated based on
the Kaplan–Meier method. The key secondary endpoint of change in eGFR
(MDRD4) from randomization tomonth 12was analyzed using an analysis of
covariance (ANCOVA) model, with treatment group, pretransplant HCV
status and eGFR (MDRD4) at randomization as covariates. Based on this
model, a noninferiority test was performed with a noninferiority margin of
6 mL/min/1.73 m2 at a one-sided 0.0125 significance level. A similar
ANCOVA analysis was performed for the change in eGFR from randomiza-
tion to month 24.
Efficacy and renal function analyses were based on the intent-to-treat (ITT)
population, comprising all randomized patients. On-treatment renal function
(eGFR) analyseswere carried out as supportive analyses, and included eGFR
values taken up to 2 days after study drug discontinuation. Safety analyses
other than renal function were performed on the safety population, which
included all randomized patients who received at least one dose of
randomized study drug.
Results
Patient population
The ITT population comprised all 719 randomized patients
(EVR þ Reduced TAC 245, TAC Elimination 231, TAC
Control 243). Study medication was discontinued before
month 24 in 104 patients (42.4%) in the EVR þ Reduced
TAC group and 79 patients (32.5%) in the TAC Control
group (Figure 1). In the TAC Elimination group, 166 patients
1,379 screened
1,148 entered the run-in period
818 attended randomization visit
166 discontinued study
medication
64 adverse events
1 abnormal laboratory value
1 abnormal test procedure
9 protocol deviation
21 unsatisfactory
   therapeutic effect
3 death
1 graft loss
8 consent withdrawal
56 administrative problem*
1 lost to follow-up
1 missing
104 discontinued study
medication
70 adverse events
4 abnormal laboratory value
7 protocol deviation
3 unsatisfactory
   therapeutic effect
5 death
3 graft loss
4 consent withdrawal
6 administrative problem
1 lost to follow-up
1 missing
79 discontinued study
medication
44 adverse events
2 abnormal laboratory value
7 protocol deviation
7 unsatisfactory
   therapeutic effect
7 death
2 graft loss
5 consent withdrawal
5 administrative problem 
329 discontinued run-in 
109 abnormal laboratory value
91 adverse events
52 protocol deviation
20 abnormal test procedure result
17 graft loss
15 withdrew consent
12 death
3 administrative reasons
10 missing
719 randomized
231 TAC Elimination 243 TAC Control
99 did not meet inclusion/exclusion
criteria at point of randomization
245 EVR+Reduced TAC
174 completed study
65 completed study medication 
204 completed study
164 completed study medication
202 completed study
141 completed study medication
*Including patients ≤ 180 days postrandomization who were converted to standard treatment
Figure 1: Patient disposition.
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(71.9%) discontinued study medication prematurely, includ-
ing patients up to 180 days postrandomization who
converted to standard treatment according to the protocol
amendment. In total, 202, 204 and 174 patients in the
EVR þ Reduced TAC, TAC Control and TAC Elimination
groups, respectively, completed the 24-month study (141,
164 and 65 on studymedication at 24months; Figure 1). The
treatment groupswerewell balanced in terms of risk factors
for chronic renal failure, including age, gender, pretransplant
HCV infection and the incidence of diabetes (Table 1).
Immunosuppression
In the EVR þ Reduced TAC group, tacrolimus tapering
began after everolimus whole blood trough levels were
confirmed to be in the target range (3–8 ng/mL). Immedi-
ately after initiation of everolimus (month 1), median C0
tacrolimus levels declined, reaching 5.7 and 5.2 ng/mL,
respectively, at months 2 and 3. From month 6 onwards
median C0 tacrolimus trough levels remained below 5.0 ng/
mL reaching 4.5 ng/mL at month 12 and 3.8 ng/mL at
month 24 (Figure S1).
Table 1: Demographics and baseline characteristics (ITT population)
EVR þ Reduced TAC
N ¼ 245
TAC Elimination
N ¼ 231
TAC Control
N ¼ 243
Age (years) 53.6 (9.2) 53.2 (10.8) 54.5 (8.7)
Male gender, n (%) 180 (73.5) 164 (71.0) 179 (73.7)
Race, n (%)
Caucasian 211 (86.1) 196 (84.8) 195 (80.2)
Black 4 (1.6) 6 (2.6) 9 (3.7)
Asian 4 (1.6) 8 (3.5) 5 (2.1)
Other 21 (8.6) 17 (7.4) 29 (11.9)
Missing 5 (2.0) 4 (1.7) 6 (2.5)
Body mass index (kg/m2)1 25.2 (4.2) 25.3 (4.3) 24.5 (4.2)
HCV positive at randomization, n (%) 79 (32.2) 72 (31.2) 76 (31.3)
Diabetes at randomization, n (%)1 87 (35.5) 79 (34.2) 97 (39.9)
Primary disease leading to liver transplantation, n (%)
Alcoholic cirrhosis 70 (28.6) 49 (21.2) 51 (21.0)
Hepatitis C 61 (24.9) 55 (23.8) 56 (23.0)
Hepatocellular carcinoma 44 (18.0) 32 (13.9) 36 (14.8)
Hepatitis B 16 (6.5) 17 (7.4) 15 (6.2)
Sclerosing cholangitis 8 (3.3) 20 (8.7) 12 (4.9)
Primary biliary cirrhosis 8 (3.3) 11 (4.8) 8 (3.3)
Metabolic disease 5 (2.0) 4 (1.7) 6 (2.5)
Cryptogenic cirrhosis 7 (2.9) 11 (4.8) 18 (7.4)
Autoimmune hepatitis 4 (1.6) 7 (3.0) 6 (2.5)
Acute hepatic failure 2 (0.8) 2 (0.9) 3 (1.2)
Other 20 (8.2) 23 (10.0) 32 (13.2)
MELD score2 19.2 (9.0) 19.6 (7.5) 19.0 (7.6)
Donor age (years) 48.8 (18.2) 50.0 (18.2) 48.7 (17.4)
Cold ischemia time (h) 8.4 (4.4) 7.5 (2.7) 8.0 (5.2)
Acute rejection prior to randomization, n (%)
tBPAR 15 (6.1) 10 (4.3) 13 (5.3)
BPAR 20 (8.2) 16 (6.9) 20 (8.2)
Acute rejection3 21 (8.6) 20 (8.7) 24 (9.9)
Cystatin C (mg/L) at randomization 1.7 (0.5) 1.7 (0.5) 1.7 (0.5)
eGFR (MDRD4) at randomization, mL/min/1.73 m2
Mean (SD) 81.1 (32.6) 82.6 (37.2) 78.0 (27.5)
Median (range) 77.1 (25.4–247.7) 74.9 (21.2–259.1) 75.2 (21.1–193.2)
eGFR (MDRD4) at randomization, n (%)
<30 mL/min/1.73 m2 5 (2.0) 4 (1.7) 4 (1.7)
30 to <45 mL/min/1.73 m2 24 (9.8) 22 (9.5) 23 (9.5)
45 to <60 mL/min/1.73 m2 42 (17.1) 35 (15.2) 34 (14.0)
60 mL/min/1.73 m2 174 (71.0) 170 (73.6) 182 (74.9)
1At randomization.
2MELD score based on laboratory values only.
3Clinically suspected acute rejection regardless of biopsy confirmation.
Continuous variables are shown as mean (SD) unless otherwise stated.
BPAR, biopsy-proven acute rejection; tBPAR, treated biopsy-proven acute rejection; eGFR, estimatedGFR; HCV, hepatitis C virus;MDRD4,
four-variable Modification of Diet in Renal Disease; MELD, model for end-stage liver disease.
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Mean everolimus C0 concentration was within target range
for the EVR þ Reduced TAC and TAC Elimination groups
throughout the study. At month 12, 22.9% (56/245), 34.3%
(83/242) and 20.5% (47/229) of patients in the EVR þ
Reduced TAC, TAC Control and TAC Elimination groups
were receiving corticosteroids; corresponding values at
month 24 were 11.8% (29/245), 22.3% (54/242) and 9.6%
(22/229). The mean (SD) dose of corticosteroids from
randomization to month 24 in the EVR þ Reduced TAC
arm, the TAC Control arm and the TAC Elimination group
was 0.19 (0.61) mg/kg/day, 0.12 (0.08) mg/kg/day and 0.14
(0.16) mg/kg/day, respectively.
Efficacy
As reported previously (7), primary efficacy failure (com-
posite of tBPAR, graft loss or death) atmonth 12 occurred in
6.5% (16/245) of EVR þ Reduced TAC patients and 9.5%
(23/243) of TAC Control patients (Kaplan–Meier incidence
rate 6.7% vs. 9.7%, respectively, with a difference of
3.0%, 97.5% confidence interval [CI] 8.7%, 2.6%;
p < 0.001 for a noninferiority test with a noninferiority
margin of 12%). The incidence of the primary efficacy
failure endpoint was similar between the two groups during
months 12–24 (Figure 2A). Comparability for the primary
efficacy endpoint was maintained at month 24 (10.3% in
the EVR þ Reduced TAC group, 12.5% in the TAC Control
group; difference 2.2%, 97.5% CI 8.8%, 4.4% in favor
of EVR þ Reduced TAC; Table 2). The incidence of BPAR at
month 24 was significantly lower in the EVR þ Reduced
TAC group versus the TAC Control group (Kaplan–Meier
incidence rate 6.1% vs. 13.3%, p ¼ 0.010; Table 2). By
month 24, moderate or severe BPAR had occurred in no
EVR þ Reduced TAC patients and in 10 TAC Control
patients.
The incidence of tBPAR (Figure 2B) was numerically lower
in the EVR þ Reduced TAC group. Graft loss and/or death
was similar in the two treatment groups (Table 2).
Estimated GFR
Mean eGFR (MDRD4) was similar between the EVR þ
Reduced TAC and TAC Control groups at the point of
randomization (Table 1). eGFR in the EVR þ Reduced TAC
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Figure 2: Kaplan–Meier plots for the proportion of patients
free from (A) the primary composite efficacy endpoint of
tBPAR, graft loss or death and (B) tBPAR (ITT population).
Table 2: Primary efficacy endpoint and selected secondary efficacy endpoints at month 24 (ITT population)
EVR þ Reduced TAC,
N ¼ 245
TAC Control,
N ¼ 243
TAC Elimination,
N ¼ 231
EVR þ Reduced TAC vs. TAC Control
Difference (97.5% CI) p value1
Primary efficacy endpoint2,3
n 24 29 55 –
KM incidence rate, % 10.3 12.5 26.0 2.2 (8.8, 4.4) 0.452
Secondary end points
Graft loss or death 17 (7.3) 14 (6.2) 18 (8.6) 1.1 (4.2, 6.4) 0.638
Graft loss, n (KM %) 9 (3.9) 7 (3.2) 6 (2.8) 0.8 (3.2, 4.7) 0.661
Death, n (KM %) 12 (5.2) 10 (4.4) 15 (7.3) 0.8 (3.7, 5.2) 0.701
tBPAR, n (KM %)4 11 (4.8) 18 (7.7) 42 (19.9) 2.9 (7.9, 2.2) 0.203
BPAR, n (KM %)4 14 (6.1) 30 (13.3) 52 (26.4) 7.2 (13.5, 0.9) 0.010
1Z-test (for non-different test).
2Treated BPAR (tBPAR), graft loss or death.
3Noninferiority test with noninferiority margin of 12%; p < 0.001.
4BPAR episodes occurring prior to randomization were excluded.
KM, Kaplan–Meier.
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arm was statistically superior to the TAC Control arm from
1 month after randomization until the end of the 24-month
study, although thedifference in favor of theEVR þ Reduced
TAC arm reduced slightly from months 12 to 24 (Figure 3A;
Table S1). At month 12, mean eGFR (SD) in the EVR þ
Reduced TAC and TAC Control groups was 80.6 (27.5) and
70.3 (23.1) mL/min/1.73 m2, respectively (p < 0.001); at
month 24, the corresponding values were 74.7 (26.1) and
67.8 (21.0) mL/min/1.73 m2 (p ¼ 0.007; Table 3).
The evolution of renal function from randomization to
month 24 was better in the EVR þ Reduced TAC group
versus TAC Control when estimated using the MDRD4,
CKD-EPI, Nankivell and Cockcroft-Gault formulae (Figure 4).
The key secondary endpoint, adjusted change in eGFR
(MDRD4) from randomization to month 12 posttransplant,
was superior in the EVR þ Reduced TAC group versus TAC
Control, with a difference of 8.50 mL/min/1.73 m2 (97.5%
CI 3.74, 13.27 mL/min/1.73 m2, p < 0.001 [ANCOVA]). The
change from randomization remained significantly superior
in the EVR þ Reduced TAC group at month 24 (difference
6.7 mL/min/1.73 m2, 97.5% CI 1.9, 11.4 mL/min/1.73 m2,
p ¼ 0.002). More patients in the EVR þ Reduced TAC
group versus the TAC Control group improved at least one
stratum by month 24 among those with poor renal function
(30 to<45 mL/min/1.73 m2) or moderate renal function (45
to <60 mL/min/1.73 m2; Table S2).
The evolution of eGFR over 2 years posttransplant was
similar in the TAC Elimination group to the EVR þ Reduced
TAC group in the ITT population (Figure 3A). Based on
ANCOVA analysis, the difference in adjusted change in
eGFR (MDRD4) from randomization for the TAC Elimination
group versus TAC Control was 9.22 mL/min/1.73 m2
(97.5%CI 4.39, 16.1 mL/min/1.73 m2 [ANCOVA]) tomonth
12, and 10.4 mL/min/1.73 m2 (97.5% CI 5.6, 15.3 mL/min/
1.73 m2, p ¼ 0.002) to month 24.
Patientswere stratified according toHCV serology status at
time of randomization. Among patients for whom eGFR
data were available at randomization and month 24, the
mean (SD) change in the EVR þ Reduced TAC group was
8.1 (24.5) mL/min/1.73 m2 in HCV-negative patients
versus 1.6 (33.8) mL/min/1.73 m2 in HCV-positive
patients. For the TAC Control group, the corresponding
values were 15.1 (23.9) mL/min/1.73 m2 and 4.3 (23.9)
mL/min/1.73 m2. For the TAC Elimination group the mean
change to month 24 was 8.8 (36.5) mL/min/1.73 m2 in
HCV-negative recipients and 1.5 (38.8) mL/min/1.73 m2 in
HCV-positive recipients.
Estimated GFR: on-treatment analysis
In a pre–planned analysis, on-treatment eGFR was also
evaluated using eGFR values up to 2 days after study drug
discontinuation. As in the ITT population, eGFR in the
EVR þ Reduced TAC group was significantly higher than in
the TAC Control arm by 1 month after randomization and
thereafter (all p < 0.001; Figure 3B). At month 24, mean
(SD) eGFR (MDRD4) for patients who remained on-
treatment was 77.6 (26.5) mL/min/1.73 m2 in the EVR þ
Reduced TAC group versus 66.1 (19.3) mL/min/1.73 m2 in
the TAC Control group (p < 0.001) and 86.2 (28.0) mL/min/
1.73 m2 in the TACElimination group. Asmentioned above,
the difference in favor of the EVR þ Reduced TAC arm
reduced slightly by month 24 in the ITT population, but in
the on-treatment population the mean (SD) change from
months 12 to 24 was similar in the EVR þ Reduced TAC
group and the TAC Control group (3.0 [16.2] vs. 2.8
[15.2] mL/min/1.73 m2).
Other renal function parameters
Mean (SD) serum creatinine level was similar between the
EVR þ Reduced TAC and TAC Control groups at randomiza-
tion, but significantly lower in theEVR þ ReducedTACcohort
atmonth24 (Table 3). During theperiod from randomization to
month 24, renal replacement therapy was required by seven
patients in the EVR þ Reduced TAC arm, eight patients in the
TAC Control group and four patients in the TAC Elimination
arm (2.9%, 3.3% and 1.7%, respectively).
Proteinuria (defined as 1.0 to <3.0 g/day) was present in
four EVR þ Reduced TAC patients and one TAC Control
patient at randomization and in five and three patients,
respectively, at month 24. Proteinuria was reported as an
adverse event in nine and two patients, respectively
(p ¼ 0.063). Nephrotic syndrome (3.0 g/day) was present
in no EVR þ Reduced TAC patients and one TAC Control
patient at randomization, and in no patients at month 24.
The urine protein to creatinine ratio became slightly higher
in the EVR þ Reduced TAC group versus TAC Control by
month 4 in the ITT population (Figure S2A), but for patients
on-treatment the difference was not significant
(Figure S2B). Values peaked at month 6 in the EVR þ
Reduced TAC group (mean [SD] 290 (607) mg/g, median
[range] 105 [33–4143] mg/g) and at month 2 in the TAC
Control arm (mean [SD] 264 (914)mg/g,median [range] 108
[39–10 370]) but remained below 300 mg/g in both
treatment arms at all times after randomization. Of the
10 patients in the EVR þ Reduced TAC group who had
urine protein to creatinine ratio 500 mg/g at randomiza-
tion, six showed a subsequent decline, three did not
provide a postrandomization value, and the remaining
patient had a ratio of 2254 mg/g at baseline and 3646 mg/g
at month 18 with no value recorded at month 24.
Cystatin C levelswere similar at randomization (Table 1) and
at month 24, whenmean (SD) values were 1.3 (0.4) mg/L in
both the EVR þ Reduced TAC and TAC Control groups.
Safety
Over the 24-month study period, the overall rates of
adverse events (96.3% in the EVR þ Reduced TAC group
and 97.9% in the TAC Control group) and serious adverse
events (56.3% and 54.1%, respectively) were similar
Renal Function: Everolimus and Low Tacrolimus
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Figure 3: eGFR (MDRD4) according to treatment group (A) ITT population (B) on-treatment patients. Values are shown as mean
and 95% CI.
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between groups. Hyperlipidemia, neutropenia, peripheral
edema, stomatitis/mouth ulceration and thrombocytopenia
weremore frequent in the EVR þ Reduced TAC arm, while
renal failure excluding proteinuria was more frequent in the
TAC Control group (Table 4). Discontinuation of study
medication due to adverse eventswasmore frequent in the
EVR þ Reduced TAC arm versus TAC Control (70/245
[28.6%] vs. 44/242 [18.2%]). The most frequent adverse
events leading to discontinuation of study medication were
proteinuria (eight EVR þ Reduced TAC patients and one
TAC Control), hepatitis C recurrence (six and five patients)
and renal failure (two and six patients). Pancytopenia,
leukopenia and thrombocytopenia led to discontinuation of
three, two and two patients, respectively, in the EVR þ
Reduced TAC group.
Infections occurred in 56.3% (138/245) of patients in the
EVR þ Reduced TAC group, with bacterial, viral and fungal
infections reported in 19.6%, 18.4% and 3.3%, respective-
ly. The incidence of infection in the TAC Control arm was
51.7% (125/242; 13.2% bacterial infection, 18.2% viral
infections and 6.2% fungal infections). There were no
significant differences in infection rates overall or for each
category of infection (Table 4), although therewas a trend to
more bacterial infections in the EVR þ Reduced TAC group
(p ¼ 0.067, risk difference 6.4%, 95% CI 0.2, 12.9).
Cytomegalovirus infection was reported as an adverse
event in 12 EVR þ Reduced TAC patients (4.9%) and 13
TAC Control (5.4%; Table 4).
Discussion
This is the first trial to report outcomes at 2 years in liver
transplant recipients randomized to reduced-exposure TAC
or TAC Elimination versus a standard TAC Control group.
The results demonstrate that renal function, as assessed by
eGFR, was superior at 2 years after liver transplantation in
patients randomized to EVR þ Reduced TAC at 1 month
posttransplant versus those receiving a standard tacrolimus
regimen. The superior renal function in the EVR þ Reduced
TAC arm was achieved without a penalty in terms of
efficacy: Comparable efficacy results versus the TAC
Control group at month 24 were confirmed despite very
low TAC concentrations (3–5 ng/mL). Indeed, significantly
fewer BPAR events were observed with EVR þ Reduced
TAC versus the TAC Control arm. Although enrollment into
the TAC Elimination armwas discontinued prematurely and
many patients were converted back to standard treatment,
the relatively smaller number of patientswho remained on a
Table 3: Renal endpoints at month 24 according to treatment group (ITT population)
Randomization Month 24
EVR þ Reduced
TAC
TAC
Control
TAC
Elimination p value1
EVR þ Reduced
TAC
TAC
Control
TAC
Elimination p value1
MDRD4 81.1 (32.6) 78.0 (27.5) 82.6 (37.2) 0.553 74.7 (26.1) 67.8 (21.0) 77.5 (26.2) 0.007
(mL/min/1.73 m2),
mean (SD)
(n ¼ 233) (n ¼ 227) (n ¼ 218) (n ¼ 184) (n ¼ 186) (n ¼ 163)
eGFR, CKD-EPI 78.2 (25.3) 76.5 (23.9) 78.6 (26.8) 0.455 74.1 (24.4) 67.5 (20.0) 76.5 (23.3) 0.006
(mL/min/1.73 m2),
mean (SD)
(n ¼ 233) (n ¼ 227) (n ¼ 218) (n ¼ 184) (n ¼ 186) (n ¼ 163)
eGFR, Nankivell 91.3 (27.6) 87.2 (23.7) 91.6 (28.2) 0.275 88.9 (23.3) 82.2 (18.6) 90.7 (22.6) 0.003
(mL/min/1.73 m2),
mean (SD)
(n ¼ 223) (n ¼ 209) (n ¼ 208) (n ¼ 169) (n ¼ 164) (n ¼ 148)
Creatinine clearance 87.3 (31.9) 81.3 (27.7) 88.6 (39.2) 0.069 88.3 (35.5) 80.0 (27.9) 90.3 (36.0) 0.033
Cockcroft-Gault
(mL/min), mean (SD)
(n ¼ 233) (n ¼ 227) (n ¼ 218) (n ¼ 184) (n ¼ 186) (n ¼ 163)
Serum creatinine 96 (35) 98 (34) 95 (35) 0.563 101 (36) 106 (29) 96 (34) 0.014
(mmol/L), mean (SD) (n ¼ 233) (n ¼ 227) (n ¼ 218) (n ¼ 184) (n ¼ 186) (n ¼ 163)
1Wilcoxon rank sum test for EVR þ Reduced TAC vs. TAC Control.
CKD-EPI, chronic kidney disease epidemiology collaboration; eGFR, estimated glomerular filtration rate;MDRD4, four-variableModification
of Diet in Renal Disease; SD, standard deviation.
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Figure 4: Change in eGFR from randomization to month 24
according to treatment group by different formulae (ITT
population). p values refer to EVR þ Reduced TAC vs. TAC
Control (Wilcoxon’s Rank sum test).
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tacrolimus-free regimen showed strikingly good renal
function at month 24.
The effect of treatment on renal function was apparent
early after randomization, with the difference reaching
significance by the first month (7) and peaking around
month 4. In the first 3–4 months after randomization, eGFR
remained largely unchanged in the EVR þ Reduced TAC
group but declined in the standard tacrolimus arm until
reaching a plateau at a level approximately 10 mL/min/
1.73 m2 lower than in the EVR þ Reduced TAC cohort.
Although this difference narrowed somewhat during
months 12–24 in the ITT population, the difference
between the two groups in adjusted change of eGFR
from randomization to month 24 was 6.7 mL/min/1.73 m2,
a benefit that can be considered clinically relevant.
Interestingly, the difference in eGFR at month 24 for on-
treatment patients was 11.5 mL/min/1.73 m2 in favor of
EVR þ Reduced TAC, reflecting the impact of patients
being discontinued from study medication in the EVR þ
Reduced TAC arm and then receiving higher doses of CNI.
In the TACControl arm the reversewas observed: A greater
proportion of patients with tacrolimus exposure below the
recommended target range appeared beneficial to renal
function in the ITT population (Figure 3B). Impaired renal
function at 1 year after liver transplantation is predictive of
subsequent deterioration and poor kidney function at 5
years (13–15), so it would seem likely that a benefit in renal
function might be sustained long term although this
remains speculative.
It was notable that among those patients who remained on
their randomized treatment, the difference in mean eGFR
between theEVR þ Reduced TACgroup versus the control
group (11.5 mL/min/1.73 m2) was more marked than in
the overall ITT population (Figure 3B). Results of this
preplanned on-treatment analysis provide a more accurate
assessment of the potential renal effects of an everolimus-
based low-CNI regimen.
A clear separation in tacrolimus exposure and a substantial
overall reduction of 39% was achieved in the EVR þ
Reduced TAC arm compared to TAC Control. Median C0
tacrolimus trough levels were below 6.0 ng/mL as early as
month 1 after randomization and were consistently below
5.0 ng/mL from month 5 postrandomization onward,
suggesting that the recommended target ranges for both
everolimus 3–8 ng/mL and tacrolimus 3–5 ng/mL were
Table 4: Adverse events and infections of clinical interest at month 24, N (%; safety population)
EVR þ Reduced
TAC, N ¼ 245
TAC Elimination,
N ¼ 229
TAC Control,
N ¼ 242
EVR þ Reduced TAC vs.
TAC Control
p value1
Risk difference,
% (95% CI)
Any adverse event 236 (96.3) 216 (94.3) 237 (97.9) 0.42 1.6 (4.6, 1.4)
Anemia 24 (9.8) 29 (12.7) 25 (10.3) 0.88 0.5 (5.9, 4.8)
Angioedema 6 (2.4) 4 (1.7) 5 (2.1) 1.00 0.4 (2.3, 3.0)
Ascites 11 (4.5) 14 (6.1) 11 (4.5) 1.00 0.1 (3.7, 3.6)
Cytomegalovirus infection 12 (4.9) 17 (7.4) 13 (5.4) 0.84 0.5 (4.4, 3.4)
Cardiovascular event 10 (4.1) 4 (1.7) 15 (6.2) 0.31 2.1 (6.0, 1.8)
Gastrointestinal ulcers 5 (2.0) 3 (1.3) 8 (3.3) 0.42 1.3 (4.1, 1.6)
Hepatocellular carcinoma recurrence 3 (1.2) 4 (1.7) 3 (1.2) 1.00 0.0 (2.0, 1.9)
Hyperlipidemia 66 (26.9) 63 (27.5) 28 (11.6) <0.001 15.4 (8.5, 22.2)
Incisional hernia 24 (9.8) 15 (6.6) 19 (7.9) 0.52 1.9 (3.1, 7.0)
Interstitial lung disease 2 (0.8) 1 (0.4) 2 (0.8) 1.00 0.0 (1.6, 1.6)
Malignancy 19 (7.8) 16 (7.0) 17 (7.0) 0.86 0.7 (3.9, 5.4)
Neutropenia 38 (15.5) 31 (13.5) 19 (7.9) 0.011 7.7 (2.0, 13.3)
New onset diabetes mellitus 51 (20.8) 53 (23.1) 40 (16.5) 0.25 4.3 (2.6, 11.2)
Peripheral edema 55 (22.4) 45 (19.7) 36 (14.9) 0.036 7.6 (0.7, 14.5)
Pleural effusion 15 (6.1) 7 (3.1) 13 (5.4) 0.85 0.8 (3.4, 4.9)
Proteinuria 9 (3.7) 11 (4.8) 2 (0.8) 0.063 2.8 (0.2, 5.5)
Renal failure (excluding proteinuria) 52 (21.2) 40 (17.5) 74 (30.6) 0.023 9.4 (17, 1.6)
Stomatitis/mouth ulceration 26 (10.6) 10 (4.4) 3 (1.2) <0.001 9.4 (5.3, 13.5)
Thrombocytopenia 20 (8.2) 21 (9.2) 7 (2.9) 0.016 5.3 (1.2, 9.3)
Thrombotic and thromboembolic events 18 (7.3) 13 (5.7) 14 (5.8) 0.58 1.6 (2.8, 6.0)
Thrombotic microangiopathy 0 (0.0) 1 (0.4) 0 (0.0) — —
Wound healing complications 27 (11.0) 25 (10.9) 20 (8.3) 0.36 2.8 (2.5, 8.0)
Any infection 138 (56.3) 134 (58.5) 125 (51.7) 0.32 4.7 (4.2, 13.5)
Bacterial infection 48 (19.6) 45 (19.7) 32 (13.2) 0.067 6.4 (0.2, 12.9)
Viral infection 45 (18.4) 45 (19.7) 44 (18.2) 1.00 0.2 (6.7, 7.1)
Fungal infection 8 (3.3) 17 (7.4) 15 (6.2) 0.14 2.9 (6.7, 0.8)
11Fisher’s exact test.
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achieved in the majority of EVR þ Reduced TAC patients.
Given the very low rate of BPAR in the EVR þ Reduced
TAC arm, further reduction to even lower tacrolimus
exposure ranges might be feasible after introduction of
everolimus and could be justified in order to minimize CNI-
related toxicity.
Premature discontinuation of recruitment to the TAC
Elimination arm, and switching of patients less than
6 months postrandomization to standard therapy, neces-
sarily limits interpretation of renal function in this group.
However, eGFR data were provided at month 24 by 57
patients who continued to receive their assigned tacroli-
mus-free treatment regimen throughout the study. It is
striking that in a preplanned analysis of on-treatment
patients, eGFR values for the TAC Elimination and EVR þ
Reduced TAC groups diverged after CNI discontinuation
(from month 4 posttransplant), with the TAC Elimination
group showing a sustained improvement in renal function.
At month 24, eGFRwas approximately 10 mL/min/1.73 m2
higher in the tacrolimus-free arm versus the EVR þ Re-
duced TAC group, and approximately 20 mL/min/1.73 m2
higher than the standard TAC group. Although relatively
fewer patientsweremaintained on theCNI-free regimen up
to month 24 compared to the number of patients in the
other two treatment groups who completed the 2-year
study, this marked renal benefit does suggest that
tacrolimus elimination with everolimus introduction at
month 1 after liver transplantation could be a potentially
valuable strategy for preserving renal function. Further
characterization of patientswhomay be suitable candidates
for an everolimus-based, CNI-free regimen is required, as is
exploration of different partner drugs (e.g. mycophenolic
acid) and the optimal procedure for conversion based on the
current findings and those of previous trials of CNI
elimination (5,6).
There was no significant difference in the rate of wound
healing events between the EVR þ Reduced TAC and the
TAC Control arms (11.0% vs. 8.3%, respectively), although
it should be borne in mind that the study was not powered
to detect differences in relatively infrequent adverse
events. In kidney transplantation, recent studies which
have employed a similar regimen of concentration-con-
trolled everolimus with reduced-exposure CNI therapy to
that used here have reported no association with an
increased rate of wound healing complications (1,16).
Moreover, in the current trial introduction of everolimus
was delayed until day 30, avoiding the period of highest risk
for healing complications related to the initial transplant
procedure. Bacterial infections, while numerically higher in
the EVR þ Reduced TAC arm, did not differ significantly
and the overall rate of infection was similar between the
two groups.
Nephrotic proteinuria was rare. The mean urine protein to
creatinine ratio was slightly higher in the EVR þ Reduced
TAC arm versus the TAC Control group, a difference that
was significant in the ITT population but not among
patients who remained on treatment. It remained below
the subnephrotic range throughout the study with only 1
of the 10 patients with overt proteinuria (500 mg/day) at
randomization experiencing worsening proteinuria during
the study. Overall, aggravation of proteinuria in mainte-
nance liver (17) and kidney (18,19) transplant patients
after conversion to mTOR inhibitors, particularly in
patients with significant existing proteinuria, does not
seem as concerning in the de novo liver transplant
setting. Nevertheless, careful monitoring of proteinuria in
future studies, over longer follow-up periods, is
important.
The study design included several features that merit
consideration. Use of an open-label design was mandated
by the need for careful adjustments in everolimus and
tacrolimus exposure. The absence of blinding, however,
would not have influenced laboratory measurements of
renal function. Stratification according to HCV status and
renal function at the time of randomization helped to
achieve balance between the treatment arms in terms of
the likely evolution of renal function (20,21). The control
regimen—tacrolimus with steroids either continued or
withdrawn not earlier than 6 months posttransplant—
represents a standard immunosuppressive regimen after
liver transplantation, although addition of mycophenolic
acid (particularly during the early posttransplant period to
facilitate lower tacrolimus exposure) has become increas-
ingly widespread since the study protocol was developed.
Introduction of everolimus at day 30 and exclusion of
patients without patent hepatic vasculature by hepatic
Doppler ultrasound were considered appropriate strategies
to minimize the possible risk of transplant-related wound
healing events and hepatic artery thrombosis reported
using sirolimus in de novo liver transplant recipients. For the
assessment of renal function, eGFR is known to be less
reliable than direct measurements (22,23) but multiple
methods of estimating GFR were used to confirm the
findings obtained with the MDRD4 formula and showed
consistent results. In terms of generalizability, the study
population showed similar eGFR values at the time of
randomization to those seen in the general liver transplant
population (13).
In conclusion, results from this randomized trial demon-
strate that introduction of everolimus with reduced-expo-
sure tacrolimus at 1 month after liver transplantation
achieves robust preservation of renal function at 2 years
posttransplant with no compromise in efficacy. These
resultsmirror findings at 1 year (7), with nomarked changes
in efficacy or safety profile during months 12–24. While
elimination of tacrolimus at 4 months posttransplant was
associated with an increased rate of acute rejection, those
patients who remained on the tacrolimus-free regimen at
2 years exhibited excellent renal function, with mean eGFR
approximately 20 mL/min/1.73 m2 higher than in the
standard-tacrolimus group.
Renal Function: Everolimus and Low Tacrolimus
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Figure S1: Tacrolimus C0 concentration according to
treatment group from time of randomization (ITT
population). Values are shown as median with 5th and
95th percentiles.
Figure S2: Median urinary protein to creatinine ratio
according to treatment group in (a) ITT population (b)
on-treatment population. P values refer to comparisons
of EVR þ Reduced TAC versus TAC Control.
Table S1: eGFR (MDRD4, mL/min/1.73 m2) according to
treatment group (ITT population). Values are shown as
mean (SD)
Table S2: Shift in eGFR (MDRD4, mL/min/1.73 m2) strata
from randomization to month 24 according to treatment
group. Percentage values at month 24 calculated using the
number of patients in that category at randomization as the
denominator
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